United States Genomics Market Overview, 2030

The Human Genome Project (HGP), which was officially finished in 2003, marked the beginning of an impressive journey in genomic sequencing. This worldwide effort to map the entire human genome established the foundation for current genomic medicine. Since then, the advancement of CRISPR-Cas9 technology has further transformed the field by making gene editing precise, affordable, and efficient, paving the way for advanced biomedical research and gene treatments. Early adoption of genomics in medical research was greatly aided by the United States, especially through the initiatives of organizations like the National Institutes of Health (NIH). This made it possible to use genomic methods in research on infectious diseases, personalized medicine, and cancer. At the same time, direct-to-consumer (DTC) genetic testing businesses like 23andMe and AncestryDNA experienced explosive expansion in the private sector. By providing inexpensive genetic testing to the general public, these businesses democratized access to genomic data, but they also posed serious issues regarding data privacy and the accuracy of interpretation. Federal funding, particularly via the NIH, played a crucial role in promoting research and development (R&D) in genomics by backing both translational and basic science research programs. Significant programs like the Precision Medicine Initiative and the Cancer Genome Atlas were created as a result of this federal support. Notwithstanding these advancements, ethical issues remain, particularly regarding the privacy of genetic data. As genetic testing becomes more common, there is a risk that insurers, employers, or third-party businesses will improperly use sensitive information. Issues regarding the security of genetic data, data ownership, and consent for secondary usage are still unresolved. Although regulatory frameworks like HIPAA provide some protection, they are insufficient to keep up with the rapid advancement of technology. One of the most urgent ethical dilemmas in contemporary biomedical science is finding a balance between the great potential of genomic research and the necessity of protecting personal genetic information.

According to the research report, ""US Genomic Market Overview, 2030,"" published by Bonafide Research, the US Genomic market is anticipated to grow at more than 14.94% CAGR from 2025 to 2030. The fusion of genomics with AI-driven drug discovery is one of the main factors contributing to this expansion. AI algorithms can process large genomic datasets to find disease targets, foresee how drugs will work, and speed up the creation of personalized treatments. This convergence of AI and genomics is impacting drug development pipelines and shortening the time to market for new therapies. The growing number of FDA approvals for genomic-based treatments is another significant advancement in the industry. In recent years, the FDA has authorized a number of groundbreaking gene therapies, like those for genetic diseases like spinal muscular atrophy (SMA) and certain cancers using CAR-T cell treatments. These regulatory milestones indicate increased trust in genomic medicine as a conventional treatment method. Thermo Fisher Scientific and Illumina are two of the main companies in this market. Illumina is known for its next-generation sequencing (NGS) platforms, such as the MiSeq and NovaSeq systems, which are commonly used in research and clinical settings. On the other hand, Thermo Fisher provides a wide range of products, from NGS equipment to bioinformatics solutions and genomic reagents. Both firms are making significant investments to enhance their genomic diagnostic skills. The growing need for personalized medicine is one of the major trends influencing the market. Genomic diagnostics are essential in determining specific genetic differences that affect illness susceptibility and medication effectiveness as patients and healthcare providers look for more personalized treatment choices. With genomics anticipated to play a fundamental role in modern medicine, this move toward individualized healthcare is likely to support continued rapid expansion in the genomics market in the years to come.

U.S. genomics market is divided into products and services, each of which makes a distinct contribution to the industry's expansion. Genomics includes consumables, instruments, and software platforms as its products. Reagents, sequencing kits, enzymes, primers, and microarrays are all considered consumables since they are necessary for the preparation and processing of genetic material. The term ""instruments"" refers to cutting-edge equipment utilized for reading and analyzing genetic sequences, such as DNA analyzers, microarray scanners, PCR systems, and Next-Generation Sequencing (NGS) platforms. The powerful bioinformatics platforms included in the software are used to analyze, visualize, and interpret enormous genomic datasets. Major firms providing these products are Illumina, Thermo Fisher Scientific, and Pacific Biosciences. In the United States, the main drivers of product demand are NGS and PCR technologies. These products have applications in a wide range of fields, including clinical diagnostics and drug development, with a focus on oncology, infectious disease diagnostics, and reproductive genetics. Hospitals, research institutions, pharmaceutical firms, contract research organizations (CROs), and biotechnology startups are among the main consumers of genomic goods in the United States. Their applications cover a wide range of fields, including cancer diagnosis, rare genetic illness screening, and population-wide genetic research. The genomics industry offers services such as whole genome and exome sequencing, genomic data interpretation, CRISPR-based gene editing services, biobanking, and genetic counseling. Some of the top service providers are GeneDx, Invitae, and BGI Americas, as well as an expanding number of niche CROs. These services are essential for vital research in the fields of clinical diagnostics, drug development, precision medicine, and public health genomics. Among the key sectors that use genomic services are prenatal medicine, neurology, oncology, and cardiology. Smaller laboratories and clinics are increasingly able to access these cutting-edge analyses thanks to cloud-based genomic services.

The Genomic market by technology is divided into Next-Generation Sequencing (NGS), PCR, Microarrays, Sanger Sequencing, Flow Cytometry and Others. The U.S. genomics industry is fueled by a number of cutting-edge technologies, each of which is essential to the development of research, diagnostics, and personalized therapy. At the forefront is next-generation sequencing (NGS), which allows for the quick and high-throughput sequencing of whole genomes and specific regions. The widespread use of NGS in the United States is driven by both clinical diagnostics and academic research, with a focus on oncology, rare disease diagnosis, and infectious disease monitoring. With quicker, less expensive sequencing platforms that have made genome sequencing available even at the consumer level through businesses like 23andMe and AncestryDNA, market leaders like Thermo Fisher Scientific and Illumina continue to innovate and dominate the NGS industry. In genomic labs, the polymerase chain reaction (PCR), notably quantitative PCR (qPCR), is still a crucial technique for increasing DNA segments, making it an essential tool for applications in mutation detection, gene expression research, and infectious disease diagnostics, as seen by its widespread use during the COVID-19 pandemic. Although somewhat replaced by next-generation sequencing (NGS), microarrays are still often used for gene expression profiling, pharmacogenomics, and large-scale genome-wide association studies (GWAS). By providing microarray platforms catered to clinical research and personalized healthcare, businesses like Agilent Technologies and Affymetrix have maintained their relevance. Regarded as the gold standard for sequencing shorter DNA segments, Sanger sequencing remains useful for validating NGS results or for regular clinical diagnostic panels that demand targeted analysis. In the fields of immunogenomics, cancer immunotherapy research, and stem cell research, the combination of genomics and cellular analysis that is flow cytometry is essential. It complements genomic profiling data because it can assess complicated cell communities. Developing technologies, such as CRISPR-Cas9 gene editing, single-cell sequencing, and nanopore sequencing from Oxford Nanopore, are becoming more popular and are helping drug discovery and functional genomics.

Genomics is crucial in diagnostics, particularly in oncology, where genomic sequencing is used to find cancer-specific mutations, guide targeted therapies, and enhance patient outcomes. Another developing area is cardiology, where genetic tests aid in identifying inherited heart diseases, enabling the implementation of early intervention measures. By offering conclusive diagnoses where traditional approaches have failed, genomic diagnostics for rare diseases have revolutionized patient treatment. Furthermore, genomics of infectious diseases, especially during the COVID-19 pandemic, showed how sequencing can monitor viral mutations in real-time, thereby informing public health actions. Prenatal screening, carrier testing, and pharmacogenomics are diagnostic uses. Genomic technologies greatly aid in the process of finding and developing drugs. Pharmaceutical businesses can utilize genomic data to discover new drug targets, forecast how patients would react to treatments, and create companion diagnostics to improve treatment accuracy. To expedite the development of customized drugs, many biotech and pharmaceutical businesses in the United States work with genomics companies. Precision medicine is another key application, strongly backed by government programs like the NIH's All of Us Research Program. Genomic profiling is becoming more and more common for customizing treatments based on a person's genetic makeup, especially in the fields of oncology, neurology, and metabolic disorders. Genomics is utilized in agricultural and animal genomics to create high-yielding, disease-resistant crops and animals, which supports sustainable agriculture. Genomic selection in livestock increases productivity and disease resistance, while crop genomics helps to raise the nutritional value. In the United States, genomics is utilized in a variety of fields, including forensics, ancestry studies, and population genomics. With businesses like 23andMe and AncestryDNA dominating the industry, personal genomics has become mainstream due to consumer demand for direct-to-consumer (DTC) genetic testing. U.S. genomics market is still growing throughout the research, healthcare, agricultural, and consumer industries, fostering advancements in biotechnology and personalized care.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Genomic Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product & Services
• Products
• Services

By Technology
• Next-Generation Sequencing (NGS)
• PCR
• Microarrays
• Sanger Sequencing
• Flow Cytometry
• Others

By Application
• Diagnostics (Oncology, Cardiology, Rare Diseases, Infectious Diseases, Others)
• Drug Discovery and Development
• Precision Medicine
• Agriculture & Animal Genomics
• Other Applications Show more